Last Updated : February 25, 2020
Details
Generic Name:
Pembrolizumab
Project Status:
Not filed
Manufacturer:
Merck Canada Inc.
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Tumour Type:
Gastrointestinal
Indications:
Adult patients with unresectable or metastatic microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer whose tumours have progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, as monotherapy.
Review Status:
Not Filed
Recommendation Type:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
Clarification:
CADTH is unable to recommend reimbursement because a submission was not filed by the manufacturer.
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : February 25, 2020